top of page
Search

DermR Health

  • arcs52
  • Nov 15, 2024
  • 1 min read

Updated: Nov 18, 2024

DermR Health is revolutionising skin cancer diagnostics with the DermRÆ Patch, a world-first microneedle device that painlessly collects live skin cells for rapid genomic analysis. Our novel patch can be easily sent to any partnered genomics or pathology laboratory, where it is tested against our proprietary RNA Gene Assay, which measures gene expression and can detect cancerous changes in just a few cells, screening against the spectrum of skin cancers, including Melanoma.


Our goal is to replace traditional biopsies as a first-tier approach for skin cancer detection with a less invasive, more efficient screening method. Moreover, the DermRÆ Patch supports Next-Gen Sequencing for full human genome analysis, opening new avenues for research into hundreds of other diseases. We're not just advancing skin cancer detection; we're setting new standards in dermatology and beyond.





 
 
 

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.

© 2024 ARCS Australia Pty Ltd

bottom of page